Wednesday, April 22

Healthcare

Alnylam falls after full data for heart drug that can rival Pfizer’s

09/01/20241 Min Read

Alnylam data drug falls full heart Pfizers rival

Previous ArticleHUTCHMED pulls regulatory submission for Takeda-partnered cancer drug in China

Next Article Emergent stock jumps as FDA clears smallpox vaccine for people at high risk of mpox